Search results for "cell carcinoma"

showing 10 items of 519 documents

Residents'corner July 2013. sQUIZ your knowledge! A dome-shaped pigmented papule appeared in a congenital lesion.

2013

ejd.2013.2109 Auteur(s) : Alejandro Martin-Gorgojo alejandromartingorgojo@aedv.es, Maria Gavrilova Department of Dermatology, Clinical University Hospital of Valencia, University of Valencia. Av Blasco Ibanez 17, 46010 Valencia, Spain What is your diagnosis (figure 1)? The answer is on the next page. The answer to sQuiz: Basal cell carcinoma appearing in a nevus sebaceous Excision and histopathological examination of the element showed a basaloid tumor. Mucin, pigment, cytological atypia and several mitotic [...]

Aged 80 and overPathologymedicine.medical_specialtySkin Neoplasmsbusiness.industryPapuleDermatologyNevus Sebaceous of JadassohnHistopathological examinationmedicine.diseaseUniversity hospitalDermatologyCongenital LesionCarcinoma Basal CellNevus sebaceousAtypiaMedicineHumansBasal cell carcinomaFemalemedicine.symptombusinessEuropean journal of dermatology : EJD
researchProduct

Conservative management of T1G3 transitional cell carcinoma of the bladder. Risk factor analysis in 165 selected patients

2003

INTRODUCTION AND OBJECTIVE: The management of TlG3 transitional cell carcinoma of the bladder (TCCB), is still controversial. Some Authors support an immediate radical cystectomy. BCG is considered the treatment of choice. Limited encouraging experiences are reported with intravesical chemotherapy. Objectives; Evaluating a selected population of 165 patients with TlG3 TCCB, in absence of Tis, treated conservatively with TUR plus adjuvant intravesical therapy. METHODS: Between January 1976 and December 1999, 165 patients with TlG3 bladder tumors were treated by TUR plus adjuvant intravesical therapy. Patients with previuos T1G3, Tis, more than 3 tumors or greater than 3 em were excluded. A s…

BCGradical cystectomytransitional cell carcinoma of the bladder (TCCB)Settore MED/24 - Urologia
researchProduct

Pigmented desmoplastic trichilemmoma

2016

Desmoplastic trichilemmoma (DT), the pseudomalignant variant of conventional trichilemmoma described by Hunt et al in 1990, displays a superficial lobular growth pattern of glycogen-rich cells with peripheral nuclear palisading surrounded by a thickened basement membrane. DT differs from its conventional counterpart by showing a central hyalinized area with epithelial cords and strands mimicking invasive carcinoma. We report a case that fully satisfies the criteria for DT and, in addition, shows an extensive melanocytic cell component and prominent melanin deposition. To our knowledge, a pigmented variant of DT has not been reported and should be recognized in order to appropriately face th…

Basement membranePathologymedicine.medical_specialtyHistologyPigmented basal cell carcinomaTrichilemmomaInvasive carcinomaDermatologyDesmoplastic trichilemmomaBiologymedicine.diseaseOuter root sheathPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisPeripheral Nuclear PalisadingmedicineDifferential diagnosisJournal of Cutaneous Pathology
researchProduct

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

2015

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T an…

Blood Glucoselcsh:MedicineBlood Pressureurologic and male genital diseasesTriglycerideBody Mass IndexAntineoplastic Agentchemistry.chemical_compoundRetrospective StudieRenal cell carcinomalcsh:ScienceMultidisciplinaryKidney NeoplasmKidney NeoplasmsSurvival RateEverolimuCholesterolDisease ProgressionHumanmedicine.drugResearch ArticleAdultmedicine.medical_specialtyAdolescentUrologyBlood sugarAntineoplastic AgentsYoung AdultInternal medicinemedicineCarcinomaHumansEverolimusCarcinoma Renal CellTriglyceridesNeoplasm StagingRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)EverolimusCholesterolbusiness.industrylcsh:RCarcinomaRenal CellAdolescent; Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Carcinoma Renal Cell; Cholesterol; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Lipid Metabolism; Neoplasm Staging; Retrospective Studies; Survival Rate; Triglycerides; Young Adult; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Lipid metabolismBiomarkermedicine.diseaseLipid Metabolismrenal; carcinomaBlood pressureEndocrinologyAgricultural and Biological Sciences (all)chemistryPharmacodynamicslcsh:QbusinessBiomarkersPloS one
researchProduct

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H…

2020

Abstract Objectives Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. Materials and methods A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characte…

Bridged-Ring CompoundsMaleCanadaCancer Researchmedicine.medical_specialtymedicine.medical_treatmentTaiwanMedizinCetuximabPlatinum CompoundsKaplan-Meier EstimateSystemic therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsRepublic of KoreaConfidence IntervalsmedicineHumans030223 otorhinolaryngologySurvival analysisAgedRetrospective StudiesChemotherapyCetuximabSquamous Cell Carcinoma of Head and Neckbusiness.industryHead and neck cancerAustraliaMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaConfidence intervalEuropeRegimenMethotrexateTreatment OutcomeOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleTaxoidsFluorouracilNeoplasm Recurrence LocalOral SurgerybusinessBrazilmedicine.drugOral Oncology
researchProduct

Angiogenesis-related prognosis in patients with oral squamous cell carcinoma-role of the VEGF +936 C/T polymorphism.

2014

BACKGROUND: The aim of the study was the immunohistological assessment of VEGF-single nucleotide polymorphism (SNP)-related angiogenic activity in oral squamous cell carcinoma (OSCC) in correlation with prognosis. METHODS: Fifty OSCC samples were immunostained with CD31-antibodies. Mean microvessel density (MVD) and staining intensity were determined and associated with clinicopathological/prognostic features as well as with the VEGF +936C/T SNP. RESULTS: A significant higher MVD could be seen for T3 and T4 compared with T1 and T2, N > 0 vs. N0 as well as G3–G4 vs. G1–G2 OSCCs (all: P < 0.05). A higher MVD was also associated with increased and earlier rates of local relapses, more metastas…

CD31AdultMaleVascular Endothelial Growth Factor ACancer Researchmedicine.medical_specialtyPathologyAngiogenesisVEGF receptorsSingle-nucleotide polymorphismBiologyGastroenterologyPolymorphism Single NucleotideDisease-Free SurvivalPathology and Forensic MedicineInternal medicinemedicineSNPHumansAlleleAgedAged 80 and overNeovascularization PathologicSquamous Cell Carcinoma of Head and NeckNeoplasms Second PrimaryMiddle AgedPrognosisImmunohistochemistryStainingSurvival Ratestomatognathic diseasesOtorhinolaryngologyHead and Neck NeoplasmsLymphatic Metastasisbiology.proteinCarcinoma Squamous CellPeriodonticsFemaleMouth NeoplasmsOral SurgeryNeoplasm Recurrence LocalImmunostainingJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Unusual Neuroendocrine Differentiation in a Small Round Cell Angiosarcoma: A Potential Histologic Mimicker of Superficial Ewing Sarcoma.

2018

Neuroendocrine differentiation or aberrant expression of neuroendocrine markers is very uncommon in angiosarcomas (AS) and creates a challenging differential diagnosis with other superficial or soft tissue tumors. Herein, we report a new case of superficial AS presenting as a tumor lesion on the little finger of the right hand of a 52-year-old man. The tumor displayed CD56, chromogranin-A, and synaptophysin immunoreactivity. Tumor cells were positive for vascular markers (CD31, FLI1, ERG, D2-40, VE-cadherin, VEGR1,2, and 3), CD99, and EMA, but were negative for S100, CK (AE1/AE3), CK20, polyomavirus, and myogenic (desmin and myogenin) and melanocyte markers (melan-A and HMB45). Ki67 immunos…

CD31MalePathologymedicine.medical_specialtySkin NeoplasmsBiopsyCD99HemangiosarcomaDermatologySarcoma EwingNeuroendocrine differentiationPathology and Forensic MedicineDiagnosis DifferentialFingers030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePredictive Value of TestsBiopsymedicineBiomarkers TumorHumansAngiosarcomaIn Situ Hybridization FluorescenceCell Proliferationbiologymedicine.diagnostic_testMerkel cell carcinomabusiness.industryCell DifferentiationGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma Neuroendocrine030220 oncology & carcinogenesisSarcoma Small CellSynaptophysinbiology.proteinSarcomabusinessThe American Journal of dermatopathology
researchProduct

Precision sampling fuels precision oncology: an evolutionary perspective.

2021

Intratumor heterogeneity (ITH) develops in malignant tumors. Precision sampling that captures this tumor variability is essential for the implementation of precision oncology. We highlight the necessity to update current sampling protocols and implement a strategy to ensure ITH detection and characterization. A cost-effective strategy for such sampling has been modeled in clear cell renal cell carcinoma (CCRCC).

Cancer ResearchComputer sciencePerspective (graphical)Sampling (statistics)medicine.diseasecomputer.software_genreBiological EvolutionKidney NeoplasmsClear cell renal cell carcinomaOncologyIntratumor heterogeneityPrecision oncologymedicineHumansData miningPrecision MedicinecomputerCarcinoma Renal CellTrends in cancer
researchProduct

Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running…

2007

Abstract Purpose: Renal cell carcinoma (RCC) accounts for 2% to 3% of all malignancies. It represents one of the most radiation- and chemotherapy-resistant tumors and surgical resections are only effective in organ-defined disease. However, RCC is an immunogenic tumor with response rates to immunotherapies between 10% and 20% of the treated patients. Due to the currently inefficient therapies and the low 5-year survival rates of RCC patients, novel diagnostic, prognostic, and therapeutic markers are urgently needed for this disease. Experimental Design: Proteome-based approaches were used to identify (a) differentially expressed proteins in RCC compared with normal kidney epithelium and (b)…

Cancer ResearchKidneyPathologymedicine.medical_specialtyCell growthKidney metabolismBiologyurologic and male genital diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsmedicine.anatomical_structureOncologyRenal cell carcinomamedicineCarcinomaBiomarker (medicine)ImmunohistochemistryneoplasmsKidney cancerClinical Cancer Research
researchProduct

Differentially methylated genes in proliferative verrucous leukoplakia reveal potential malignant biomarkers for oral squamous cell carcinoma

2021

Objectives: To explore the pathophysiology of proliferative verrucous leucoplakia (PVL) through a methylated DNA immunoprecipitation and high-throughput sequencing (MeDIP-seq) case-control study. Materials and & nbsp; Methods: Oral biopsies from ten PVL patients and five healthy individuals were obtained and used to compare their epigenetic patterns. Network biology methods and integrative analyses of MeDIP-seq and RNAseq data were applied to investigate functional relations among differentially methylated genes (DMGs). The value of selected genes as malignant biomarkers was evaluated in a large cohort of oral squamous cell carcinoma (OSCC) patients from TCGA.& nbsp; Results: A total of 464…

Cancer ResearchMeDIP-seqBiology03 medical and health sciences0302 clinical medicinemedicineHumansMethylated DNA immunoprecipitationEpigeneticsDifferential methylation030223 otorhinolaryngologyBone morphogenesisSquamous Cell Carcinoma of Head and NeckOral cancerGATA3CancerBiomarkerDNA Methylationmedicine.diseaseRNAseqDifferentially methylated regionsOncologyOral squamous cell carcinomaCase-Control Studies030220 oncology & carcinogenesisDNA methylationCancer researchProliferative verrucous leukoplakiaMouth NeoplasmsEpigeneticsGene ontologyLeukoplakia OralOral SurgeryBiomarkersHOXD10
researchProduct